Phase 2 Rheumatoid Arthritis Trial, Recruiting NCT07632846 Sponsor: Horus University Condition: Rheumatoid Arthritis
Back to Rheumatoid Arthritis

Phase 2 Rheumatoid Arthritis Trial, Recruiting

NCT07632846
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with active rheumatoid arthritis based on recognised international classification guidelines from 2010.
  • People whose disease activity score across 28 joints (a standard measurement of rheumatoid arthritis severity) is above 2.6, indicating active disease.
  • People between 18 and 60 years of age.
  • Both men and women are eligible.
  • People who are currently taking methotrexate alongside other standard arthritis treatments.
  • People who are able to read and sign a written consent form agreeing to take part in the trial.

Who may not be able to join:

  • People who have kidney or liver disease.
  • People who have a known allergy or sensitivity to the medications being studied.
  • People who are currently taking antioxidant supplements.
  • People who have a history of psychiatric (mental health) disorders.
  • People who are taking the steroid medication prednisolone at a dose higher than 15 mg per day.
  • People who are currently being treated with a type of advanced arthritis medication known as biological disease-modifying drugs.
  • People who are pregnant or breastfeeding.
  • People who have a history of irregular heartbeat or a heart condition known as prolonged QT interval (a specific abnormality seen on a heart tracing).
  • People who are taking any medications known to affect heart rhythm in a way associated with prolonged QT interval (confirm with trial site for a list of specific medications).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 01028275001

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Horus University
Registry
ClinicalTrials.gov
Start date
19 May 2026
Est. completion
1 October 2026

Where this trial is recruiting

🇪🇬 Egypt

Primary endpoints

Change in Disease Activity Score (DAS28)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov